Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) [Phase 3]

View source ↗

Summary

Phase 3 trial of pembrolizumab vs investigator's choice for advanced esophageal/esophagogastric junction carcinoma after first-line therapy; completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Carcinoma
• Esophagogastric Junction Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Carcinoma, Esophagogastric Junction Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2019-11-20